MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181 E-mail: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 20210344 2021; 29th June 2021

To BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai: 400 001. Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Outcome of the Board - Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015

Pursuant to Notice of Board meeting dated 15th June 2021 the Board meeting was held on today Tuesday, 29th June 2021 at 2.00 p.m. at 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai: 400001 and has approved the following:

 The Board discussed and approved the Annual Financial Statements together with accounting policies, schedules, and explanatory notes, as reviewed by the Audit Committee, for the year ended 31st March 2021 in accordance with provision of the Companies Act, 2013.

The Board discussed and chose to reduce activity due to the on-going Covid-19 pandemic in India as well as its customers markets. The view taken was unavailability of persons in the target customer offices in their countries due to revised work culture i.e. work from home. The business being such that requires personal presentation & relationship building has taken a tremendous hit & is unlikely to see any possibility of revival with the addition of new customers in the immediate future due to uncertainties on account of the prevalent worldwide pandemic, even business from the company's regular customers is likely to shrink by 50% in the short term. Add to this the devastating effect the second ware of Covid-19 has had in India, leading to massive disruptions across supply of chain. Given this, we do not see significant improvement till overseas markets open completely. Till such time, the Company will complete pending orders and any new order received from regular customers. The Company will temporarily reduce activities till a clearer picture emerges.

The management has considered the possible effects, if any that may impact the carrying amounts of inventories, receivables, goodwill, intangibles, and other assets. In making the assumptions and estimates relating to the uncertainties as at the balance sheet date in relation to recoverable amounts, the management has considered subsequent events, internal and external information and evaluated economic conditions prevailing as at the date of approval of these financial results.



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS CHEM Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181 E-mail: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



The management expects no impairment to the carrying amounts of these assets. The Management will continue too closely monitor any changes to future economic conditions and asses its impact on the operation.

The Company has sufficient liquidity to meet its financial obligations. There is no major impact on the collection from our customers and we are also making regular payments to our suppliers, employees, and other concerned persons. The liquidity position of the company is in comfortable zone.

After Careful consideration and review of financial audited accounts for the year ended on 31st March, 2021 were approved by the Board.

- 2. The Board approved the Audited Financial Results for the guarter/year ended on 31st March 2021, as reviewed by the Audit Committee, in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 3. The Board noted and took on records the Audit Report for the year ended 31st March 2021, as placed before the Board being the Unqualified Report. The approval of the Board was accorded to submit a declaration on auditor's report with unmodified opinion pursuant to the SEBI Circular no. CIR/CFD/ CMD/56/2016 dated May 27, 2016, and Notification no. SEBI/LAD-NRO/2016-17/001 dated May 25, 2016.
- 4. Retirement of directors by rotation, Mrs. Grace Ramu Deora (DIN 00312080), Director, will retires by rotation and is eligible for re-appointment at the ensuing Annual General Meeting.
- 5. Appointment of Secretarial Auditors, Approved the appointment of M/s. Ragini Chokshi & Co., Company Secretaries, Mumbai as Secretarial Auditors for the financial year 2021 - 2022.
- 6. Appointment of Internal Auditors, Approved the appointment of M/s Haren Sanghvi & Associates, Chartered Accountants, as Internal Auditors of the Company for the financial year 2021-22.
- 7. Directors Report, The Directors' Report to the shareholders on the Accounts and affairs of the company for the financial year 2020-21, Management Discussion & Analysis and the various statements/documents to be attached to Directors' Report pursuant to Section 134 of the Companies Act, 2013 were approved.
- 8. Annual General Meeting, The 49th Annual General Meeting of the Company has been fixed on Saturday, 25th September 2021 at 3.00 P.M. at the Registered Office of the Company at Sambava Chambers, 4th Floor, Sir P. M. Road, Mumbai - 400 001 The copies of the 49th Annual Report of the Company together with the Notice of the Annual General Meeting will be sent/uploaded as soon as these are ready for dispatch to the shareholders.

Produc

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181 E-mail: <u>info@amphray.com</u> Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544

- 9. Book Closure, The Register of Members and Share Transfer Books of the Company will remain closed form Friday 17th September 2021 to Saturday, 25th September 2021 (Both days Inclusive) for the purpose of taking records of the shareholders at the Annual General Meeting.
- The Board took note on Register of contracts with related party and contracts and Bodies etc. in which directors are interested [Pursuant to section 189(1) and rule 16(1)] [Form MBP-4]. (A) Contract or agreements with any related party under section 188 or in which any director is concerned or interested under sub-section (2) of section 184 for the quarter ended 31st March 2021. (B) Name of the bodies corporate, firms or other association of individuals as mentioned under sub-section (1) of section 184, in which any director is having any concern or interest for the quarter ended 31st March 2021.
- 11. Board Meeting commenced at 2.00 p.m. and concluded at 3.45 p.m.

You are requested to take note of the same. Thanking you, Yours faithfully, For **TRIOCHEM PRODUCTS LIMITED**

RAMU'S. DEORA_ DIRECTOR DIN: 00312369 Place: Mumbai



Pune Address : 123, Sohrab Hall, 21 Sassoon Road, Opp. Jehangir Hospital, Pune - 411001 • T : 020 4906 7177 E : info@kdg.co.in • W : www.kdg.co.in

Independent Auditor's Report on the Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Τo,

The Board of Directors of Triochem Products Limited

Opinion

We have audited the accompanying statement of Financial Results of Triochem Products Limited ("the company") for the quarter ended March 31, 2021 and the year to date statement for the period from April 01, 2020 to March 31, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these Financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net loss and other comprehensive income and other financial information for the quarter ended March 31, 2021 as well as the year to date statement for the period from April 01, 2020 to March 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Financial Results

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation of these Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard

Kanu Doshi Associates LLP

prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statement or, if such disclosures are inadequate, to

modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

 Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

The annual financial results include the results for the quarter ended 31 March 2021 being the balancing figures between the audited figures in respect of the full financial year and the published audited year to date figures up to the third quarter of the current financial year.

For Kanu Doshi Associates LLP Chartered Accountants Firm Registration No: 104746W/W100096

KUNAL SUMANT VAKHARIA

Digitally signed by KUNAL SUMANT VAKHARIA Date: 2021.06.29 15:47:40 +05'30'

Kunal Vakharia

Partner

Membership No: 148916 UDIN: 21148916AAAAFD5465 Suburne du

Place: Mumbai Date: June 29, 2021

TRIO MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS CHEM Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181 E-mail: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 20210339 2021; 29th June 2021

To **BSE** Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai: 400 001. Security Code No. 512101 - ISIN No.: INE331E01013

Dear Sir / Madam.

Sub: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements), Regulation 2015

The Board of Directors of the Company at its meeting held on 29th June, 2021 has approved the Audited Financial Results of the Company for the year ended 31st March, 2021 and we hereby declare that the Statutory Auditors of the Company, M/s. Kanu Doshi Associates LLP., Chartered Accountants, (FRN: 104746W/W100096) have issued an Audit Report with unmodified opinion thereon.

This declaration is issued in compliance with the provisions of the Regulation 33(3)(d) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended by the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) (Amendment), Regulation 2016 vide notification no. SEBI/LAD-NRO/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

The Declaration may kindly be taken on your records.

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA **DIRECTOR & CEO** DIN: 00312369

Prod Mumbai

Basic / Diluted EPS

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001 website: www.triochemproducts.com CIN: L24249MH1972PLC015544 AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021 (Rs. in lakhs) Except EPS Year Ended **Quarter** Ended Particulars Sr DECEMBER MARCH 31, MARCH 31, No MARCH 31, MARCH 31, 31, 2020 2020 2021 2020 2021 (Audited) (Unaudited) (Audited) (Audited) (Audited) (Refer Note (Refer Note No. 5) No. 5) 1 Income (a) Revenue from Operations 773.48 394.50 1,147.66 1,393.84 2.003.18 7.54 0.16 33.38 13.38 46.63 (b) Other income 781.02 394.66 1,181.04 1,407.22 2,049.81 Total Income from operations Expenses: (a) Cost of materials consumed (0.00)644.87 968.86 0.33 544.16 32.77 602.73 602.73 37.55 (b) Purchase of stock-in-trade (c) Changes in inventory of finished goods, work-in-progress and stock-in-trade 125.29 360.19 251.69 13.41 354.67 (d) Employee benefits expenses 16.39 16.74 30.41 66.91 82.33 10.90 1.37 2.47 5.78 22.97 (e) Finance costs (f) Depreciation and amortisation expense 3.54 3.46 4.11 13.88 16.68 26.64 112.64 111.57 (g) Other expenses 37.41 21.40 **Total Expenses** 787.06 404.26 895.56 1,465.33 1,594.63 Profit / (Loss) from ordinary activities before exceptional items (1-2) (6.04) (9.60) 285.48 (58.11) 455.18 3 4 Exceptional items Profit / (Loss) before tax (3 +/- 4) (6.04) (9.60) 285.48 (58.11) 455.18 5 6 Tax expense Current tax (0.77)(0.00)73.31 (0.75)117.33 Deferred tax 0.32 (2.42)(0.63)(12.66)(2.43)(0.45) (2.42) 72.68 (13.41) 114.90 **Total Tax expenses** Profit / (Loss) for the period (5 + -6)(5.59) (7.18)212.80 (44.70) 340.28 8 Other comprehensive income, net of income tax A. (i) Items that will be reclassified to profit or Loss (ii) Income tax relating to items that will be reclassified to profit or loss B. (i) Items that will not be reclassified to profit or Loss (1.82)0.02 0.43 (2.34)(0.30)(ii) Income tax relating to items that will not be reclassified to profit or loss 0.46 (0.11)(0.00)0.59 0.08 Total Other comprehensive income, net of income tax (1.36)0.32 0.02 (1.75) (0.22)9 Total Comprehensive income for the period (8 +/- 7) (6.95) (6.86)212.82 (46.45) 340.06 10 Paid-up equity share capital (Face value of Rs10/- per share) 24.50 24.50 24.50 24.50 24.50 11 Reserve excluding Revalution Reserves as per balance sheet of previous 1,146.69 1,193.14 accounting year 12 Earning per share (EPS) (of Rs. 10/- each) (not annualised)



(2.28)

86.86

(18.25)

138.89

(2.93)

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. <u>Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com</u> <u>Website: www.triochemproducts.com</u> Corporate Identity Number: L24249MH1972PLC015544



	STATEMENT OF AUDITED ASSETS AND LIABILI	TIES AS AT MARCH 31, 2021						
Sr	Particulars	As at	(Rs.in lakhs As at					
No		March 31,	March 31,					
		2021	2020					
		Audited	Audited					
A	ASSETS							
1	Non - Current Assets							
	(a) Property, plant and equipment	86.39	97.51					
	(b) Capital work - in - progress	3.24	3.24					
	(c) Investment property	7.72	8.11					
	(d) Financial assets	Tot Profession						
	(i) Other financial assets	7.32	7.32					
	(e) Deferred tax assets (Net)	3.92						
	(f) Other non - current tax assets	0.71	7.20					
	(g) Other non - current assets	0.87	1.19					
	Sub total - Non - Current Assets	110.17	124.63					
2	Current Assets							
	(a) Inventories	85.36	155.4					
	(b) Financial assets	0.000						
	(i) Trade receivables	139.06	1,239.89					
	(ii) Cash and cash equivalents	819.72	55.31					
	(iii) Other financial assets	0.65	0.59					
	(c) Other tax assets (net)	33.17	0.9,					
	(d) Other current assets	22.07	85.85					
	Sub total - Current Assets	1,100.03	1,537.05					
	Total - Assets	1,210.20	1,661.68					
		2,120,20	1,001100					
B	EQUITY AND LIABILITIES							
	EQUITY							
	(a) Equity share capital	24.50	24.50					
	(b) Other Equity	1,146.69	1,193.14					
	Total - Equity	1,171.19	1,217.64					
	LIABILITIES		-,					
1	Construction of the second s							
	(a) Deferred tax liabilities (Net)		9.33					
	Sub total - Non- Current Liabilities		9.33					
2	5 K K		7.5.					
	(a) Financial liabilities							
	(i) Borrowings		250.30					
	(ii) Trade payables	32.66	20 10/20					
	(b) Other financial liabilities	32.44	74.01 13.93					
	(c) Other current liabilities							
	(c) Provisions	0.93	79.80					
	(d) Current tax liabilities (Net)	5.04	9.05					
	(d) Current tax habilities (Net) Sub- total - Current Liabilities	20.01	7.50					
	Total - Liabilities	39.01 39.01	434.71					



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2021 (Rs.in lakhs) Year Ended Particulars March 31, March 31, 2021 2020 Audited Audited CASH FLOW FROM OPERATING ACTIVITIES A Net Profit before tax and Extraordinary Items (58.11) 455.18 Adjustment for: Depreciation / Amortisation 13.88 16.68 Interest Income (0.66)(2.64)Reclassification of remeasurement of employee benefits (0.30)(2.34)Interest Expenses 10.89 20.06 Investment Expenses 0.04 0.05 Sundry balance Off (5.65) (0.00)**Operating Profit before Working Capital Changes** (43.93)491.01 Adjustments for Working Capital Changes Increase/Decrease in Assets 64.10 (33.08)Changes in Inventories 70.05 802.03 Increase/Decrease Trade Receivable 1,100.83 (906.88)Increase/Decrease in other financial and non-financial assets 39.88 Increase/Decrease Trade payables (41.58)Increase/Decrease in other financial and non-financial liabilities (13.93)11.88 Increase/Decrease in Liabilities 78.62 (78.93)Changes in Provision 2.24 0.20 **Cash Generated from Operations** 1,058.85 483.66 Direct taxes paid / (refund) (33.41)(101.40)Net Cash from Operating Activities 1,025.44 382.26 CASH FLOW FROM INVESTING ACTIVITIES B Purchase of Fixed Assets including Capital Work in Progress (2.37)(3.24) Investment Expenses (0.04)(0.04)Interest Received 2.57 0.60 Net Cash Used in Investing Activity 0.16 (2.68)CASH FLOW FROM FINANCING ACTIVITIES Net (Decrease)/ Increase in Short Term Borrowings (250.30)(329.11)Interest Paid (10.89)(20.06)Net Cash Used in Financing Activity (261.19) (349.17) NET CHANGES IN CASH & CASH EQUIVALENTS (A+B+C) 764.41 30.41 **OPENING BALANCE OF CASH & CASH EQUIVALENTS** 55.31 24.90 **CLOSING BALANCE OF CASH & CASH EQUIVALENTS** 819.72 55.31

Notes:

1) The above audited financial results of the Company for the quarter and year ended March 31, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on June 29, 2021



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



2) The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).

- 3) The company has adopted Ind AS 116 effective period beginning from April 01, 2019. The effect of adoption of Ind AS 116 on the financial results is insignificant
- 4) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.
- 5) The figure for quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures of the full financial year and the reviewed year-to-date figures up to the third quarter of the relevant financial year.
- 6) The Company's operations for the financial year have been impacted by the lockdown imposed to contain the spread of Covid-19. The Management of the Company has assessed the impact of the pandemic on its financial results/position such as trade receivables, investments, inventories, trade payables and based on its best judgement and reasonable estimate, has concluded that there are no material adjustments required in the Financial Statements. However the impact assessment of Covid-19 is a continuous process, given the uncertainties associated with its duration and nature, it is not possible to estimate the future impact as at the date of approval of this financial statement. The Company continues to monitor the economic effects of the pandemic while taking steps to improve its execution efficiencies and the financial outcome.
- 7) The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 8) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIN: 00312369

DIRECTOR & CEO

Place: Mumbai Dated: 29th June, 2021



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED									
Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001									
website: www.triochemproducts.com									
CIN: L24249MH1972PLC015544									
(Rs. in lakhs - except otherwise stated)									
Extract of statement of Audited Financial Results for the Quarter and Year Ended 31st March, 2021									
Sr	Particulars	For the	For the	For the	For the	For the			
No		Quarter	Quarter	Quarter	Year Ended	Year Ended			
		Ended on	Ended on	Ended on	on	on			
		31-Mar-21	31-Dec-20	31-Mar-20	31-Mar-21	31-Mar-20			
		Audited	Unaudited	Unaudited	Audited	Audited			
1	Total Income from operations	781.02	394.66	1,181.04	1,407.22	2,049.81			
2	Net Profit / (Loss) for the period (before Tax,	(6.04)	(9.60)	285.48	(58.11)	455.18			
	Exceptional and / or Extraordinary items)								
3	Net Profit / (Loss) for the period before tax (after	(6.04)	(9.60)	285.48	(58.11)	455.18			
	Exceptional and / or Extraordinary items)								
4	Net Profit / (Loss) for the period after tax (after	(5.59)	(7.18)	212.80	(44.70)	340.28			
	Exceptional and / or Extraordinary items)								
5	Total Comprehensive Income for the period	(1.36)	0.32	0.02	(1.75)	(0.22)			
	[Comprising Profit / (Loss) for the period (after tax) and	0 5			94 20	67 4860			
	other Comprehensive Income (after tax)]								
6	Equity share capital (Face value Rs. 10/- per share)	24.50	24.50	24.50	24.50	24.50			
7	Other Equity				1,146.69	1,193.14			
8	Earnings per share (of Rs. 10/- each) (for continuing and								
	discontinued operations)								
	a) Basic (not annualized)	(2.28)	(2.93)	86.86	(18.25)	138.89			
	b) Diluted (not annualized)	(2.28)	(2.93)	86.86	(18.25)	138.89			
Notes:									
1) The above audited financial results of the Company for the quarter and year ended March 31, 2021 have been reviewed									

by the Audit committee of the Board and approved by the Board of Directors at its meeting held on June 29, 2021. 2) The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the

provisions of the Companies Act,2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).

3) The company has adopted Ind AS 116 effective period beginning from April 01, 2019. The effect of adoption of Ind AS 116 on the financial results is insignificant.

4) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.

5) The figure for quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures of the full financial year and the reviewed year-to-date figures up to the third quarter of the relevant financial year.



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



- 6) The Company's operations for the financial year have been impacted by the lockdown imposed to contain the spread of Covid-19. The Management of the Company has assessed the impact of the pandemic on its financial results/position such as trade receivables, investments, inventories, trade payables and based on its best judgement and reasonable estimate, has concluded that there are no material adjustments required in the Financial Statements. However the impact assessment of Covid-19 is a continuous process, given the uncertainties associated with its duration and nature, it is not possible to estimate the future impact as at the date of approval of this financial statement. The Company continues to monitor the economic effects of the pandemic while taking steps to improve its execution efficiencies and the financial outcome.
- 7) The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 8) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
- 9) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website, www.bseindia.com and on the Company's website www.triochemproducts.com

FOR TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIN: 00312369

DIRECTOR & CEO

Place: Mumbai Dated: 29th June, 2021

